Announcement on Voluntary Disclosure of Initiating Phase III Clinical Trial of the Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) and Enrolling the First Subject

About this update from Chengdu Olymvax Biopharmaceuticals Inc. Class A

Announcement on Voluntary Disclosure of Initiating Phase III Clinical Trial of the Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) and Enrolling the First SubjectThe abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Chengdu Olymvax Biopharmaceuticals Inc. Class A